Due to its complexity, cardiovascular clinicians have traditionally relied on primary care and endocrinologists to manage diabetes in their patients with cardiovascular disease. However, the cardioprotective effect of recently developed antidiabetic drugs has introduced many new questions for clinicians and patients alike.
The goals of this solution set are to close gaps in care related to the:
- Initiation of cardioprotective diabetic therapies – particularly SGLT2 inhibitors and GLP-1RAs – in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) or those at high risk
- Optimization of care coordination related to the management of diabetes and ASCVD risk
Expert Consensus Decision Pathways
Clinician Tools
CardioSmart Patient Tools
Heart House Roundtables
- Managing CV Disease Risk in Diabetes (2017 – 2018)
Heart House Patient Forums
- Living Well with T2D and CV Disease: Getting to the Heart of the Matter (2019)